Supernus Pharmaceuticals (SUPN) EBIT Growth (3y) (2014 - 2026)
Supernus Pharmaceuticals (SUPN) EBIT Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 29.31% |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 4.24% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 0.90% |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 1.82% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -74.25% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 27.21% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 35.42% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | -48.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.82% |
| Dec 31, 2025 | -28.36% |
| Sep 30, 2025 | -240.70% |
| Jun 30, 2025 | 2.28% |
| Mar 31, 2025 | -93.22% |
| Dec 31, 2024 | 51.98% |
| Sep 30, 2024 | 7.80% |
| Jun 30, 2024 | -12.86% |
| Mar 31, 2024 | -30.82% |
| Dec 31, 2023 | -26.48% |
| Sep 30, 2023 | -47.47% |
| Mar 31, 2023 | -43.70% |
| Dec 31, 2022 | -5.60% |
| Sep 30, 2022 | -26.79% |
| Jun 30, 2022 | -35.66% |
| Mar 31, 2022 | -57.39% |
| Dec 31, 2021 | -46.51% |
| Sep 30, 2021 | -4.54% |
| Jun 30, 2021 | -1.52% |
| Mar 31, 2021 | -25.06% |